The New York City-based Pfizer, meanwhile, will continue to use the western end of the 175-acre campus, according to reports, where it has its technical center and other operations. The two buildings that J&J will apparently take over to house its now-expanded OTC product line were being built for Pfizer's use, but that process went into a slow-down mode last year after the pharma giant announced some cost-cutting initiatives.
While a spokesman for J&J did confirm the pending arrangement, a statement issued on behalf of company chairman William Weldon indicated that final facility decisions wouldn't be formally announced until after top management of the companies' two consumer products operations worked out the details in the weeks ahead. A spokesman would not comment on details of the pending transaction, including possible sale of a portion of the Pfizer site to J&J. The acquisition adds such well-known brand names as Listerine, Visine, Sudafed, Zantac, Benadryl and Rolaids, among others, to J&J's product line.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.